NGS Testing in Plasma and Tissue
cancer
CANCER
All participants underwent plasma testing; 115 (77%) had tumor-associated variants detected (Among the 18 patients with other cancer diagnoses, 7 did not have detectable cfDNA in plasma, but 3 had potentially informative results based on cancer type (eTable 3 in Combining plasma and tissue results, 53 of 90 patients (59%) had actionable alterations identified by either method: 35 of 53 (66%) in both, 11 of 53 (21%) in plasma only, and 7 of 53 (13%) in tissue only (eFigure 2 in 